Alpha Cognition Launches ZUNVEYL (Benzgalantamine) for Mild to Moderate Alzheimer’s Disease
Wednesday, March 19, 2025
Alpha Cognition Inc. a biopharmaceutical company focused on treatments for neurodegenerative diseases, has announced the commercial launch of ZUNVEYL, a new treatment for mild to moderate Alzheimer’s disease. This marks a significant step in the company's efforts to offer new treatment options for patients and caregivers affected by the condition.
The company has deployed a nationwide salesforce to work with healthcare providers, ensuring that ZUNVEYL reaches patients who require it. The commercial strategy is aimed at the long-term care sector, which represents the largest segment for Alzheimer’s treatment and a market worth approximately $2 billion.
Alpha Cognition’s commercial team comprises professionals with extensive experience in Alzheimer’s disease and long-term care. The sales team has an average of 16 years of industry experience and 10 years of expertise in the long-term care market. Their objective is to drive the adoption of ZUNVEYL and ensure its availability to patients.
ZUNVEYL has been developed to offer an alternative treatment option for individuals with mild to moderate Alzheimer’s disease, particularly those with limited choices. With the launch underway, Alpha Cognition is engaging with healthcare providers, payers, and caregivers to facilitate patient access and increase awareness. The treatment is available in three doses (5 mg, 10 mg, and 15 mg) through prescription at pharmacies across the country.
Source: businesswire.com
